PPARγ and Its Agonists in Chronic Kidney Disease
Chronic kidney disease (CKD) has become a global healthcare issue. CKD can progress to irreversible end-stage renal diseases (ESRD) or renal failure. The major risk factors for CKD include obesity, diabetes, and cardiovascular diseases. Understanding the key process involved in the disease developme...
Saved in:
Main Authors: | Yuhua Ma, Manman Shi, Yuxin Wang, Jian Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | International Journal of Nephrology |
Online Access: | http://dx.doi.org/10.1155/2020/2917474 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
by: Tamotsu Tsukahara
Published: (2012-01-01) -
PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
by: Sarawin Harnchoowong, et al.
Published: (2017-01-01) -
New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
by: Zhanjun Jia, et al.
Published: (2014-01-01) -
Global Gene Expression Profiling in PPAR-γ Agonist-Treated Kidneys in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney Disease
by: Daisuke Yoshihara, et al.
Published: (2012-01-01) -
Role of PPARα and Its Agonist in Renal Diseases
by: Ching-Feng Cheng, et al.
Published: (2010-01-01)